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Background: Rapamycin is an immunosuppressant 
natural product, which blocks T-cell mitogenesis and yeast 
proliferation. In the cytoplasm, raparnycin binds to the 
immunophilin FKBP12 and the complex of these two 
molecules binds to a recently discovered protein, FRAP. 
The rapamycin molecule has two functional domains, 
defined by their interaction with FKBP12 (binding 
domain) or with FRAP (effector domain). We previously 
showed that the allylic methoxy group at C-7 of rapamycin 
could be replaced by a variety of different substituents. We 
set out to examine the effects of such subntitutlons on 
FKBP12 binding and on biological activity. 
Results: Rapamycin C-7-modified analogs of both K and 
S configuration5 were shown to have high aiElnities for 
FKUPl2, yet theue congeners displayed a wide range of 
potencies in splenocyte and yeast proliferation assays. The 
X-ray crystal structures of four rapamycin analogs in com- 
plexes with FKBP12 were determined and revealed that 
protein and ligand backbone conformations were essen- 
tially the same as those observed for the parent 
rapamycin-FKBP12 complex and that the C-7 group 
remained exposed to solvent. We then prepared a 
rapamycin analog with a photoreactive functionality as part 
of the C-7 substituent.This compound specifically labeled, 
in an FKBP12-dependent manner, a protein of -250 kDa, 
which comigrates with recombinant FRAE 
Conclusions: We conclude that the C-7 methoxy group 
of rapamycin is part of the effector domain. In the ternary 
complex, this group is situated in close proximity to 
FRAP, at the interface between FKAP and FKBP12. 
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Introduction 
Rapamycin (compound 1, Fig. 1) is an extraordinary 
natural product which has attracted considerable interest 
and study in disciplines spanning the fields of chemistry 
and biology [1,2]. This metabolite from Stveptomyces was 
first isolated and characterized as an antimicrobial anti- 
tumor agent in 1975. More recently, rapamycin has 
received attention as an extremely potent immunosup- 
pressant and is currently undergoing clinical investigation 
for the prevention of transplant rejection. Perhaps the 
most remarkable fact about rapamycin is that, like its 
pharmacological cousins FK506 and cyclosporin A, it falls 
into a small but undoubtedly expanding group of small 
organic molecules that function by inducing specific 
protein-protein heterodimerization [3]. 
Rapamycin and FK506 (compound 2 in Fig. 1) both 
bind with high affinity to the immunophilin FKBP12 
and inhibit its rotamase (peptidyl prolyl cis-trans isom- 
erase) activity [4]. Inhibition of this activity, however, is 
only indirectly related to the cellular effects of these 
immunosuppressive drugs [5,6]. The FKBPl2-rapamycin 
and FKBP12-FK506 complexes bind to secondary target 
proteins, apparently disrupting their critical physiological 
functions. The protein target for the FKBP12-FK506 
complex is the calcium-dependent phosphatase calci- 
neurin, an essential component of the intracellular signal- 
ing pathway linking the transmembrane T-cell receptor to 
the transcription of genes required early in activation 
such as IL-2 [7]. The structurally unrelated immunosup- 
pressant cyclosporin A (CsA) binds with high affinity to 
another family of immunophilin proteins, the cyclophilins 
(CyPs), which are structurally unrelated to the FKBPs. 
The resulting CyP-CsA complex, however, also binds to 
calcineurin, inhibiting its protein phosphatase activity. By 
inhibiting the reactivity of calcineurin, both CyP and 
FK506 block calcium-dependent T-cell activation events, 
such as the response to the interaction of the T-cell recep- 
tor with its ligand. In contrast, the FKJ3P12-rapamycin 
complex does not bind to calcineurin, nor does 
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rapamycin block calcium-dependent signaling or its 
result, entry into the cell cycle. Instead, rapamycin has 
been shown to block T-cell responses to IL-2, pre- 
venting the activation of p70s” kinase (~70”‘~) and 
cyclin-dependent kinases, and inhibiting the progression 
of the cell cycle at the Gl phase [2].Very recently, the 
target of the rapamycin-FKBP12 complex has been 
reported as a 289-kDa protein (FRAP RAFTl, RAPTl, 
SEP [S-11]), which is thought to be a lipid kinase, and 
has homology to the yeast TOR/DRR gene products 
112,131. The role of FRAP in activating ~70”“~ and 
cyclin-dependent kinases has yet to be elucidated. 
X-ray crystal structures of the’ FKBPl2-FK506 and 
FKBP12-rapamycin complexes have been determined at 
atomic resolution, revealing that the ligands have two 
functional domains, a binding domain and an effector 
domain [14] .The common domains of the natural prod- 
ucts (blue regions, centered on the cx-keto pipecolate, in 
Fig. 1) bind in an identical fashion within a hydrophobic 
pocket of FKBP12, whereas the dissimilar effector 
domains (red regions in Fig. 1) protrude from the protein 
and contribute to unique composite binding surfaces. In 
the complex with FK506, two regions in FKBP12, the 
40s and 80s loops (Fig. 2), have been shown to be 
required for recognition of the bimolecular complex by 
calcineurin, suggesting that these two loops, together 
with a portion of the FK506 macrocyclic ring, might 
directly interact with calcineurin [15,16]. Although no 
information is yet available on the determinants for 
recognition of the FKBPl2-rapamycin complex by 
FRAP, examination of the crystal structure of this 
complex reveals that an extended hydrophobic surface is 
formed by the same two loops of the protein and the 
trienyl region of rapamycin macrocycle. As shown in Fig. 
2, this composite surface is slightly convex; it might form 
an important part of the surface recognized by FRAP 
The crystal structure also shows that the C-7 methoxy 
group in rapamycin makes no direct contact with 
FISBP12.The position of this group, in the middle of this 
composite surface (roughly equidistant from the 40s and 
80s loops, Fig. 2), indicates that it may be important in 
the function of the effector domain. 
Fig. 1. Structures of the immunosup- 
pressive FKBP12 ligands rapamycin 
(compound :le;;d FK506 (compound 2) 
showing common binding 
domains (blue) and distinct effector 
domains (red). 
During the course of our exploration of the chemistry 
of rapamycin, we discovered that the C-7 methoxy 
group readily undergoes heterolytic cleavage under acid 
catalysis 1171. Ionization of the allylic methoxyl is 
assisted by the neighboring 1,3,5-conjugated triene, 
which presumably stabilizes the carbocation at C-7 by 
conjugation (structure 3 in Fig. 3). Under the acidic 
reaction conditions in which it is generated, this 
ambident electrophilic intermediate can be treated with 
nucleophiles, which, in most cases, are captured exclu- 
sively at the C-7 terminus. We have probed the role of 
the C-7 methoxyl in the effector domain of rapamycin 
using this chemistry and generated a series of analogs, 
including a photoreactive affinity agent. In this report, 
we describe structure-activity relationships for a limited 
number of analogs and show that the C-7 photoaffinity 
reagent labels a protein of similar electrophorrtic mobil- 
ity to FRAP.The results suggest that the C-7 position of 
rapamycin is part of its effector domain. 
Fig. 2. View of the crystal structure of the FKBPlZ-rapamycin 
complex [14]. The 40s and 80s loops are shown in yellow, the 
rest of the protein in white; rapamycin is shown in green, with 
the C-7 rnethoxy group in red. 
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Rapamycin (1) 
Fig. 3. The S,l reaction at rapamycin C-7. The 7-Me0 group can be replaced by a variety of nucleophiles IROH, RCO,H, RSH, 
ArNH,. RSO.NH ,, electron-rich aromatics. Et.SiHi bv catalvsis with triiluoroacetic acid ITFA) (CH,CI,, -40 “Cl or p-toluene sulionic 
2’ 
acid (p-TsOt$ IR6H. room temperature). 
,  
Results and discussion 
Synthesis of rapamycin C-7 analogs 
The procm of S,l substitution of the C-7 methoxy 
gt-oup of mpatnycin \VJC found to be of broad scope and 
\V;IC effected \vith a variety of catalysts (both protic and 
Lewis acids) md nucleophilic agents (e.g., alcohols, car- 
bosylic ,tcids, thiols, thioacids, aromatic amines, carba- 
tmtes, sulfonamides, electron-rich aromatics, and ally1 
silancs). Most analogs were obtained by reaction with tr- 
fluoroacetic acid at low tetnperature (-40 “C, CH,Cl,) in 
the presence of the nucleophile, except the C-7 ethers, 
\\.hich were more convet~iently prepared by solvolysis of 
rdpamvcin in the appropriate alcohol catalyzed by 
I’-toluenesulfotli~ acid. Nearly all reactions provided ntix- 
tures of C-7 diastereomeric products which were readily 
separable by cht-otnatography. In addition, silane-based 
hydride reducing reagents provided 7-detnethoxyra- 
pmlycin (cotnpound 12;Table 1) and in a process involv- 
ing ,I related stabilized C-7 carbocation. treatment of 
r+ttnyciu Lvith quinone oxidants yielded 7-detnethosy- 
7-osorapamycin (compound 13). Products of elimination 
\vet-e never isolated from reactions of rapatnycin with the 
above acids, even in the absence of added nucleophiles; 
however treatnten~ oft-aparnycin with lithium perchlorate 
itt diethy ether resulted in efficient- elimination of the 
(I-7 tnethoxv group to gmerate strreospecifically the 
dll-tr~7llZ 1 .3.3,7-tetraerte derivative. 
typically displaying rotantasr inhibitiott within the mnt 
order of magnitude as rapatnycin (KI,‘,PF = 0.5 nM).This 
is not unexpected, since all the analogs share the mnc 
binding domain. which is identical to the one itt 
rapatnycin. However, some analogs, exemplified by cotn- 
pounds 8b and 13, had sigttificantlv weaker binding 
W ‘Jpp = 25-10 nM). In general. compounds of lomw- 
affintty contain bulkier hydrophobic C-7 substituent~. 
perhaps reflecting greater C-7 steric demand or the po- 
sibility that the lipophilic C-7 substituent becomes more 
solvent-exposed upon bindittg to FKBP. In the cue of 
compound 13, the conjugated ketone at C-7 could have 
a long range effect on the conforntation of the bindittg 
domain by the ddditional constraint imposed 011 the 
tmcrocyclic ring. 
Effects of C-7 modification on FKBP12 binding 
The intracellular activity of rapatnycin is dependent upon 
its dfftnity for FKBPI 2 as w-e11 as the affinity of the resulting 
FKBP 13%rapatnycin complex for FRAP As a close approx- 
imation of FKBPI 2 afftnity, inhibition of rotanlase catalytic 
activity (reported throughout as apparent inhibition COII- 
stmts, K ‘.JpJ WI\ c eterrnined for the rapamycin congencrs ‘ 1 
using the standard chynlotrypsin-coupled assay [1X]. 
Spectroscopic analysis by NMR indicatrd th,lt in nom 
aqueous solution, the analogs mist mainly ;1s the twt~/s 
amide rotatners, but adopt two distinct macrocyclic cow 
formations depending on the specific cottfigumiott ‘tt 
C-7 (see Fig. 4). The conformation of all the 7-(S) 
epinwrs (compounds 5a-lla) is identical to the one of 
rapamycin. but quite different from the one adopted 1~) 
the 7-(R) epintm (compounds 5b-llb), as indicated b) 
the chemical shifts (both ‘H and ‘“C NMK) ;tnd ‘.-:_I 
vicinal coupling constants of tiiacrocyclic prototi~. 
Nevertheless, both C-7 stet-eochentistries sewn to be wctt 
tolerated by FKBPl2, since typically, K, differences 
between epimeric pairs were less than four- to five-fold. 
Reptwentative examples of over 100 analogs which have 
bwtt synthesized and assayed are shown it1 Table 1. A 
complete account of structurr-activity relationships for 
this class \\?I1 be reported separately.The great majority 
of analogs studied exhibited high affinity for FKUPl2, 
Effects of C-7 modification on inhibition of splenocyte and 
yeast proliferation 
Suppression of mitoffen-activated lymphocyte or spleno- 
cyte proliferation (as measured by uptake of thytnidinr) 
has in one of several forms become J standard irr IGWO 
measure ofitllnluiiosuppressant activity.The potencies of 
FK506 and, more recently, rapamycin congeners in this 
model have been corrrlated with their FKBPI 2 affinities 
and with their abilities as FKBPI 2 complexes to bind to 
calcineurin [ 191 or FKAP [8]. Similarly, the abilities of 
FK506 and rapatttyciu to arrest yeast grom:th in S and C; 1 
phase\ have been shown to be dependent upon FKBPI 3 
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Fig. 4. Determination of the conformations of compounds 10a and lob. 400.MHz ‘H NMR spectra of compound IOa (top) and com- 
pound lob (bottom). The configuration at C-7 could be determined by ‘H and 13C NMR analysis, since the spectra of each epimeric pair 
were very different from each other, but almost identical within the same epimeric series. 
[20] as well as calcineurin [21] and the FKAP-related 
DRR/TOR gene products [12]. We therefore used both 
a mouse splenocyte mitogenesis assay and a high-flux 
yeast-based assay system to study the biological profiles 
of the rapamycin derivatives reported here. 
Remarkably, modification of the C-7 position of 
rapamycin resulted in a wide range of biological activi- 
ties and, significantly, a divergence with respect to 
FKBP12 binding. Rapamycin shows an IC,,, in the 
splenocyte assay of 1 nM and an IC,,, in the yeast assay 
of 7 nM (Table 1). The C-7 methoxy group does not 
appear to be important in the activity of rapamycin 
since its removal, for example in 7-demethoxyrapamycin 
(compound 12), leads to an analog with an identical 
biological profile to rapamycin itself. In general, analogs 
with small groups at C-7 (e.g. compounds 6a and 6b) 
showed activities in both splenocyte and yeast assays 
comparable to those of rapamycin, regardless of the C-7 
configuration. Some analogs that retained high FKBP12 
affinity showed markedly decreased activity in the cellu- 
lar assays (e.g., compounds 7a, 9), suggesting that their 
C-7 substituents prevented binding of the associated 
FKBP12 complex to FRAP Intermediate between these 
extremes, some analogs possessed measurable, yet less 
potent (10 to loo-fold weaker than rapamycin) yeast 
and splenocyte activities. Some analogs also showed a 
divergence of potencies between the yeast and spleno- 
cyte assays (e.g., compounds 5b, 7a, lob), presumably 
due to heterologies in the FRAP and TOR proteins. 
Differences in binding of an FK506analog/FKBP 
complex to yeast and mammalian calcineurins have sim- 
ilarly been reported [22]. Although it is possible that 
these analogs differ in their ability to penetrate cells, the 
results of these studies appear consistent with the notion 
that the C-7 methoxy substituent comprises part of the 
rapamycin effector domain, closely approaching, if not 
contacting, FRAP in the ternary complex, although it is 
not essential for binding. There seem to be some con- 
straints associated with the size of the C-7 substituent, 
so that bulky, rigid groups, such as the 7(R)-1’,3’,5’- 
trimethoxybenzene ring in 9, interfere with the binding 
interaction between FRAP and the FKBP12-rapamycin 
complex. To provide more direct evidence for the 
notion that the C-7 substituents are in close proximity 
to FRAP, we designed and synthesized a C-7 radio- 
photoaffinity derivative of rapamycin. 
Photoaffinity labeling of a putative FKBPl2-rapamycin 
binding protein 
The hypothesized positioning of the rapamycin C-7 sub- 
stituent at the interface between FKBP12 and the 
rapamycin target (recently identified as FRAP) and the 
tolerance to a variety of C-7 substitutions, suggested that 
an appropriate C-7 substituent could be used to carry a 
reactive functional group that could specifically tag the 
target partner protein. Indeed, a benzyloxy substituent 
appeared to be ideal since the corresponding benzyl 
ether (compound 14a,Table 1) retained potent biological 
activity and the aromatic ring in 14a could tolerate small 
meta and para substituents, such as those in compounds 
15a and 16a, without a large decrease in activity. 
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Table 1. Biological activities of rapamycin C-7 analogs.” 
R Compound FKBP T Cell Yeast 
Ki (nM) IGo (nM) IC12 (nM) 
,-,,ohk 1 0.6 1 7 
-0Me 4 1 30 20 
‘,-WI 5a 3.5 10 10 
-0Et 5b 4 200 15 
,,,,$,,,c> 6a 1 4 4 
- SM? 6b 1 4 4 
*,~~NHCOLhk 7a 4.5 >I 0000 170 
-NHU12Me 7b 3.7 2500 220 
Ik0 
stm’,-, 0 mk 8a 9 1000 225 
h\rO 
43 \ , O?e 8b 38 >I 000 400 
IleO 
-D ,-, OlLlC~ 9 7 >lOOO >10000 
,MeO 
““4-J 10a 3 20 12.5 
-9 lob 6 20 3 
“,,(-J lla 10 11 28 
II 
-5 llb 1 .5 70 28 h 
II 
-Ii 12 1 2 8 
=o 13 29 300 210 
,&cl 14a 5 6 6 
,,,(J -4 \ / 15a 7 50 20 
NO? 
,,,,la(wI 16a 1 45 6 
9 ’ ’ Ni 
17a 30 90 60 
,,,() 
Y-7 configuration is 7-(s) (same as rapamycin) for Xa and 
7-(R) for Xb. 
We therefore prepared a compound with suitable func- 
tional groups for a radiophotoaffinity label (compound 
17a), containing a 4-azido-3-‘~5~iodo]-benzyloxy group 
at (I-7. The synthesis of 17a was accomplished starting 
with the iodination of 4amino methyl benzoate (com- 
pound 18) as shown in Fig. 5. After conversion of the 
amine to the azide, the ester was reduced to provide the 
required l-azido-3-iodo bcnzyl alcohol (compound 19). 
A route was devised to incorporate 12’1 at ,I late stage, to 
mlmmize the number of radioactive synthetic intermed- 
ates. The iodo alcohol 19 was therefore subjected to 
palladiuiil-catalyzed ctannylation to give the arylstannane 
20. Reaction of 19 and rapamycin with JI-TsOH in 
CHICI, at room temperature produced a 1 : 1 mixture of 
separable C-7 epimcrs 17a and 17b in 66 ‘%I yield (Fig. 
5). Incorporation of compound 20 into the C-7 position 
of rapamycin produced compourid 21a in lower yield 
due to competing protodestannylatior1 (I-+ ‘%I yield, 
epimer 21b not isolated). Exchange of the stannane in 
21a with carrier-free Na”“I in the presence of chlo- 
raminr-T gave 1’ 251] 17a (47-65 ‘%I radiochemical yield, 
l-7 mCi scale. 0649 ‘%I radiochemical purity). 
Compound 17a displayed an affinity for FKBP12 some 
two orders of magnitude lower than rapamycin (Table 1) 
but activity in the splenocyte assay was reduced to no 
greater an extent, suggesting that the affinity of the 
FKUPI ?-compound 17a complex for the target protein 
was comparable to that of the rapamycin complex. An 
inactive rapamycin derivative, compound 22a , was syn- 
thesized as a control by rrtroaldol cleavage [23] of the 
nlacrocylic ring using ZnCl, in THF at room temperature 
(65 ‘%I yield, Fig. 5). Comp&md 22a exhibited FKBP12 
affinity similar to that of 17a (K, = 30 and 73 IIM for 17a 
and 22a, respectively), but. lacking a fLmctiona1 effector 
domain, shelved no significant activity in the splenocyte 
assay.Thus, we expected compounds 17a and 22a to inter- 
act similarly \vith FKBP family members, but to interact 
dif&rently with the do\vnstream target protein. 
A major protein band of molecular mass -250 kDa (~250) 
\vas strongly and reproducibly labeled by compound 17a. 
This protein was strongly labeled in CTLL-20 extracts or 
whole cells, and was also present in Jurkat and THP-1 cells 
(Fig. 6). We were able to separate ~250 fi-0111 the majority 
of cytosolic FKBI’ by ultracentrifugation. Labeling of 
~250 was enhanced after addition of exoger~ous FKBP, 
suggesting that it is dependent on FKBP (Fig. 6). 
The speciticity of p250 labeling by 17a was evaluated by 
competition experiments. Low levels of rapamycin abol- 
ished labeling, while higher concentrations produced high 
backgrounds (Fig. 7). We interpret this result as indicating 
the displacement of compound 17a from FKBP by high 
concentrations of rapamycin, leading to loss of labeling 
specificity. FK506 at low concentrations failed to compete 
with 17a for labeling of-p250. Higher concentrations pro- 
duced background labeling of proteins and reduced the 
~250 signal (Fig. 7). The inactive seco-derivative, 22a, 
failed to compete ‘it any concentration tested (Fig. 7). 
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The results show that 17a specifically labels a protein of compound 22a could not. Compound 17a does not label 
250 kDa that is present in all three cell lines examined, FKBPl2 itself.These findings are consistent with a role for 
two of which are ofT-cell origin and one that is mono- ~250 as a downstream target for the rapamycin-FKESP12 
cyte-like. Labeling was dependent on FKBP12; rapa- complex. Western blotting with antiserum to FRAP 
mycin could compete for labeling, whereas FK5C)G and showed that FRAP was present in our cell extracts (Fig. 
8).Three other bands that cross-react with the antiserum 
to FKAP were also seen. We do not know what relation- 
- FKBP + FKBP ship, if any, these proteins have to FRAl’, but imaging of 
CJTCJT radioactivity in photolabeled extracts showed that only 
one band was labeled by the photoaffinity reagent. This 
Fig. 5. Synthesis of the photoaffinity 
label reagents 17a and 22a. (a) N- 
iodosuccinimide (NIS), cat. H,SO,, 
MeCN, 67 %; (b) NaNO,, cone HCl, 
then NaN,, 95 “ill; (c) LiOH, MeOH; (d) 
isobutyl chloroformate, Et,N, then 
NaBH,, 62 % steps c-d; (e) (Bu,Sn),, 
(Ph,Pi,PdBr2, toluene, dimethyl for- 
mamide (DMF), 100 “C, 62 %; (f) com- 
pound 19 !excess), p-TsOH, CH2,CI,, 
room temperature, 66 % of 1:l C-7 
epimers; (g) compound 20 (excess), 
p-TsOH, CH,,CI,, room temperature, 
14 % of 21a; (h) chloramine-T, Na’?‘l; 
(h) ZnCI,, tetrahydrofuran ITHFI, room 
temperature, 65 %. 
band co-migrated with recombinant FRAP, consistent 
with the possibility that compound 17a is labeling FRAI! 
Atomic models of selected FKBPI 2 complexes 
Four C-7 rapamycin analogs (compounds 4, 6a, 6b and 9) 
complexed with FKBP 12 were selected for detailed struc- 
tural studies by single crystal X-ray diffraction. C~onlpound 
4 allowed the direct comparison of rapamycin and C-7 
epirapamycin, while 6a and 6b provided an independent 
assessment of an epimeric pair with a modest increase in 
steric bulk. Compound 9 allowed the structural alterations 
induced by a bulky hydrophobic substituent to be studied. 
The protein components of all four complexes show the 
same folding topology found in the initial 
FKBPl2-rapamycin structure [17], and as can be seen in 
Table 2, the root-mean square deviations for main chain 
atoms are 0.16, 0.13, 0.14 and 0.50 A for compounds 4, 
Fig. 6. FKBPl Z-dependent photoaffinity labeling of ~250 by 
6a, 6b and 9, respectively. For the smaller C-7 substituents 
rapamycin derivative 17a. CTLL-20 (C), Jurkat (J), and THP-1 (T) (in 4, 6a, and 6b) the complexed ligands show no signifi- 
cell extracts were centrifuged at 130 000 x g and the pellets were cant conformational differences from complexed 
washed to remove endogenous FKBP. Pellets were resuspended 
in PBS, incubated with 10 nM 17a in the presence or absence of 
rapamycin (Table 3), and the root-mean square deviations 
10 PM FKBP12 for 30 min and irradiated with a Hg vapor UV 
are 0.30, 0.37 and 0.55 A. Not surprisingly, compound 
lamp. Following gel filtration to remove unbound radiolabel, the 6a is closer to rapamycin than 6b or 4, but the overall 
protein fraction was electrophoresed on 10 % polyacrylamide picture is one of little conformational dependence on C-7 
gel and visualized by autoradiography. stereochemistry for the smaller substitu>nts. The bound 
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Fig. 7. Competition tor labeling of ~250 
bY rapamycin, FK506 or 
seco- 
rapamycin derivative 22a. Washed 
pellets from a 130 000 x g spin of jurkat 
txtract were reconstitute2 with 0.5 (*M 
FKBPl2 and preincubated with com- 
petitor at the indicated concentrations 
ior 30 min before being irradiated in the 
presence of 10 nM rapamycin-derived 
photoaffinity label 17a. Protein fractions 
were subjected to 6 ‘%I SDS-PAGE and 
visualized by autoradiography. 
conformations of thece ligands do not appear to be 
especially cencitive to stercochmCstry at C-7 (Fig. 9). 
While the FKBI’I 3 con~plexes with cmnpounds 4, 6a, 
and 6b mwe all isomorphous \x?th rapamycin, the 
complex lvith compound 9 wx not, and the bulky C-7 
substituent resulted in different intermolecular interactions 
md different crystal pJcking. The crystal structure of 
FKLJI’I ?-compound 9 was complicated, with four molr- 
cuks. # 1, #2, #3 md #1. in the asymmetric unit. T\vo 
pairs of molecules. #I-#2 aid #3-#1, mm-e related by a 
noncr~stallographic two-fold axis and had no significant 
diff>rcnces, although the trinwthoxyphenyl group of the 
#lb#3 pair chom~d some disorder. The differences 
betmwn # 1 and #?I were quantitative, not qualitative. 
LSoth # 1 md #3 had significmt maiwchain deviation\ 
il-0111 the FKl31’13-rapamycin structure in the regions cen- 
tered on residue 33 and 88 (Fig. 9). The I-egion centered 
on residue 33, mhich is not nc‘a- the bound ligdnd, is on 
the surt;~ce of the protein md in the contxt Lvith other 
molecules and svmmt.trv-l-elated nzoleculcs. Thus the 
dc\iations prob,lbly rtwlt’fiwn the altered cr\;$tnl packing 
and lntem~olecular internctions. The deviation in the 
region around residue 8X appears to be J direct result of 
the bulky substituent at C-7. Residue X8 ig in the tip of 
the 80s loop. lvhich is ntm- the ligand binding site and 
knmvn to be importmt in binding of FKUI’I 2-FK.506 to 
7 
(  r  
.I . 
1  ..“I 
-  20 0 
., 
Fig. 8. The protein labeled by compound 17a co-migrates with 
FRAP. Jurkat cell extract was photolabeled with rapamycin 
derivative 17a and, following 7 % SDS-PAGE, exposed on a 
phosphorimager screen to visualize radioactive proteins (lane 
1 I. Jurkat extracts ilane 2) were subjected in parallel with 
recombinant FRAP (lane 3) to 7 ‘%, SDS-PAGE and Western 
blotted with antiserum to FRAP. 
calcineurin. The bulky triIn~tho?cvph”“yl substituznt at 
C:-7 forces the residues at the tip ot‘the 80s loop to mow 
away slightly from the ligand and is retlected in the 
changes seen in T,lble 3.The trilnethox?:phenyl substituent 
also occupies the region of space thought to be crucial for 
FRAP binding and thus could account fix the observed 
lack of cellular xtivity (Table 1). 
Significance 
Rapamycin, a potent and clinically important 
immunosuppressant, mediates a precise disruption 
of cell cycle progression in T-lymphocytes by 
inducing a protein-protein dimerization event. 
Rapamycin has two domains, one binding with 
nanomolar affinity to FKBP12, the other (the 
effector domain) forming a new binding surface 
when complexed with FKESP12, which allows 
binding to a recently identified 289-kDa protein of 
unknown function (FRAP). Synthetic modiflca- 
tions to the binding domains of rapamycin and 
the structurally related FKBP ligand FK506, along 
with X-ray crystallography, have provided some 
insight into the FKBP-rapamycin interaction. 
However, synthetic modifications to the rapamycin 
effector domain have been extremely limited. The 
remarkable reactivity of the C-7 methoxy group of 
rapamycin has allowed us to replace this group 
with a wide range of substituents. 
Here we report that modifications to the C-7 
center of rapamycin result in divergences between 
the biological effects of the rapamycin analogs 
and their ability to bind FKBP12.Thus, it is plau- 
sible that the C-7 substituent may form part of 
the FRAP-binding surface. Some groups of sub- 
stantially greater steric demand than the methoxy 
group still allowed FRAP binding, suggesting that 
the C-7 substituent may lie in an interfacial space 
between FKBP12 and FRAP The X-ray crystal 
structures of complexes of several of these analogs 
with FKBP12 show that the overall fold of the 
protein and the ligand conformation are essen- 
tially identical to those observed for the parent 
rapamycin bound to FKBP12. 
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Fig. 9. Superimpositions of crystal structures of complexes of FKBPI 2 with rapamycin analogs. Superimpositions of (a) FKBPl2-com- 
pound 4 (7.epi-rapamycin), (b) FKBPlZ-compound 6a (7-thiomethyl), (c) FKBP12-compound 6b (7-epi-thiomethyl) and (d) 
FKBPlZ-compound 9 (7-epi-trimethoxyphenyl, molecule $3 is shown) with FKBPlZ-rapamycin [I41 are shown. Rapamycin is 
depicted as red; rapamycin derivatives are depicted as yellow. Proteins are shown as a backbone traces only (FKBPIZ in complex with 
rapamycin: green, FKBP12 in complex with the analog (FKBP-X): blue). Structures were superimposed using a least-squares fit of 
protein backbone heavy atoms. 
We have extended the application of this chem- 
istry to introduce a photoreactive radiolabel into 
the C-7 position and demonstrated a selective, 
FKBP12-dependent labeling of a T-cell protein of 
apparent molecular mass 250 kDa, which may be 
FRAP Further manipulation of the rapamycin 
effector domain, particularly at C-7, may yield 
rapamycin analogs with enhanced FRAP aflinity 
and therefore greater therapeutic eflicacy. 
Materials and methods 
Preparation of compounds 5a and 5b 
To a solution of rapamycin (2.2 g, 2.41 mmol) m EtOH (100 
ml) at room temperature was added p-TsOH (1.3 g, 12 mmol) 
and the reaction was monitored for disappearance of 
rapamycin. After 2 h, the mixture was diluted with EtOAc, and 
the organic extracts washed with saturated NaHC03, brine 
and dried over Na>SO,. The crude material was purified by 
preparative silica gel high-pressure liquid chromatography 
(HPLC; lichrosphere Si60 column; eluted with 42:42:15:2-4.5 
Hex:CHC&:EtOAc:MeOH), to give compound 5a as a 
white solid (0.46 g) along with a mixture of 5a:5b (-1 :I, 1.6 g, 
93 %I overall yield).This latter material was repurified by silica 
gel HPLC to provide 5a (760 mg) along with 5b (785 tug). 
Data for 5a: ‘H NMK (CI>Cl,, 400 MHz, 4:l mixture of 
tvuns:ris amide rotatners; data for the tYdM.s-rotamer): S 6.375 
(dd,J = 14.8, 10.3 Hz, 1 H, H-4). 6.300 (dd,] = 14.8,9.6 Hz, 1 
H, H-3), 6.134 (dd,] = 14.9, 9.6 Hz, 1 H, H-2), 5.940 (d,J = 
10.3 Hz, 1 H, H-5), 5.533 (dd.] = 14.Y, 9.2 Hz, 1 H, H-l), 
5.108 (d,-1 = Y.7 Hz, 1 H, H-26), 5.29 (m, 1 H. H-20), 5.17 
(rn, 1 H, H-22). 3.799 (s, 1 H, OH-13), 4.173 (d,J = 5.9 Hz, 1 
H, H-28), 3.87 (m, 1 H, H-9), 3.775 (dd,] = 7.8,7.0 Hz, 1 H, 
H-7), 3.714 (d,J = 5.Y Hz, 1 H, H-29), 3.576 (br d,] = 14.0 
Hz, 1 H, H-16), 3.407 (s, 3 H), 3.338 (s, 3 H), 3.161 (dq, 
Table 2. Root-mean-square deviations oi, FKBPI 2-X structures 
from the FKBPl2-rapamycin structure (A). 
x: 4 6a 6b 9 (%l) 9 (#3) 
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J = 9.X,6.9 Hz, 1 H), 2.587 (ddJ = 17.0,6.3 Hz, 1 H, H-23), 
1.751 (s, 3 H), 1.662 (s, 3 H), 1.152 (t,J = 6.9 Hz, 3 H), 1.098 
(d,J = 6.7 Hz, 3 H), 1.047 (d,J = 6.5 Hz, 3 H), 0.991 (d,J = 
6.6 Hz, 3 H), O.Y51 (d,J = 6.6 Hz, 3 H), 0.917 (d,J= 6.7 Hz, 3 
H), 0.668 (q,-J = 12.0 Hz, 1 H, H-41); ‘% NMR (CDCI,, 
100.6 MHz, data for the trdfrS-rotamer): 6 215.5, 208.2, 192.6, 
160.3, 166.7, 140.0, 136.4, 136.0, 133.4, 130.2, 12Y.0, 126.7, 
126.5, 9X.5, 84.7, 84.4, 82.3,77.2,75.6,73.9, 67.2, 63.3, 5Y.3; 
MS (ESI+/NH’OAc) m/z 950 (M+Na+), 945 (M+NH,+); 
UV (MeOH) AI113X 267, 277, 289 nm. L1ata for 5b: ‘H NMR 
(CDCI,, 400 MHz, 2.5:l mixture of tr~s:ris amide rotamers; 
data for the tmrls-rotamer): 6 6.365 (dd,_l = 14.2, 11 .O Hz, 1 H, 
H-4), 6.185 (ddJ = 14.2, 10.4 Hz, 1 H,H-3),6.12-6.05 (m,2 
H, H-2 and H-5), 5.471 (ddJ = 14.4,9.1 Hz, 1 H, H-l), 5.321 
(d,J = 10.3 Hz, 1 H, H-X), 5.25-5.20 (m, 2 H, H-22 and H- 
2(l), 3.260 (br s, 1 H, H-28), 4.10~4.04 (m, 1 H, H-9), 4.050 (s, 
1 H, OH-13), 4.012 (d,J = 3.6 Hz, 1 H, H-29), 3.698 (dd,J = 
8.1. 1.5 Hz, 1 H, H-7), 3.50-3.41 (111, 2 H, H-16 and H from 
C;-OEt), 3.394 (s. 3 H), 3.332 (s, 3 H), 3.232 (dtJ = 13.4, 
7.0 Hz, 1 H, H from C,-OEt), 2.718 (dd,] = 17.4, 2.7 Hz, 1 
H, H-23), 2.376 (dd,j = 17.4, 8.5 Hz, 1 H, H-23), 1.750 (c, 3 
H). 1.654 (s, 3 H), 1.180 (t,J = 7.0 Hz, 3 H), I.059 (d,J = 6.7 
Hz, 3 H), 1.005 (d,J = 6.6 Hz, 3 H), O.Y41 (d,_l = 6.5 Hz, 3 
H). O.Y25 (d,] = 6.5 Hz, 3 H), 0.863 (d,_l = 6.6 Hz, 3 H), 
0.646 (q,J = 12.0 Hz, 1 H, H-41); MS (ESI+/NH@Ac) m/z 
930 (M+Na+), Y45 (M+NH,+). 
Preparation of compounds 7Oa and 10b 
To a solution of rapamycin (1.2 g, 1.31 mmol) and furan (3.8 
ml, 52 mmol) in CH,Cl, (52 ml) at -10 “C was added trifluo- 
roacetic acid (1.7 nil, 22 mmol), and the solution was stirred for 
3 h at -40 “C. The reaction mixture was then partioned 
between EtOAc and brine. The organic extracts were dried 
with Na,SO+ filtered, concentrated in mcrdo and purified by 
chromatography (silica gel; elution with 200:50:42.5:7.5 
CH2C12:Hex:EtOAc:MeOH,) to yield 10a (740 mg, 5Y %I) and 
lob (380 mg, 30 ‘XI). Data for 10a: ‘H NMR (CDCl,, 
400 MHz, 4: 1 mixture of rvurzs:i-is amide rotamers; data for the 
trurrs-rotamer): 6 7.290 (d,] = 1.6 Hz, 1 H,Ar H-5’), 6.3Y-6.32 
(m, 2 H. H-4 and H-3), 6.289 (dd,_l = 3.2, 1.6 Hz, 1 H,Ar H- 
4’). 6.16-6.1 1 (III, 1 H, H-2), 6.0226.00 (m, 1 H, H-5), 6.006 
(d,J = 3.2 Hz. 1 H,Ar H-3’), 5.615 (dd,_l = 15.1, X.2 Hz, 1 H, 
H-l), 5.424 (d,J = 9.8 Hz, 1 H, H-26), 5,336 (d,j = 4.9 Hz, 1 
H, H-20), 5.191 (q,J = 5.5 Hz, 1 H, H-22), 5,096 (s, 1 H, OH- 
13), 4.200 (dJ = 6.0 Hz, 1 H, H-28), 3.85-3.W (III, 1 H, H-Y), 
3.734 (d,] = 6.0 Hz, 1 H, H-29),3.697 (dd,J = 8.5, 8.1 Hz, 1 
H, H-7), 3.408 (s, 3 H), 3.357 (s, 3 H), 2.944 (ddd,] = 11.3, 
8.5, 4.1 Hz, 1 H, H-42), 2.68’) (d,J = 6.2 Hz, 2 H, H-23), 
1.775 (s, 3 H), 1.559 (s,3 H), 1.136 (d,] = 6.8 Hz. 3 H), 1.051 
(d,J = 6.6 Hz, 3 H), 1.006 (d,] = 6.5 Hz, 3 H), 0.990 (d,J = 
6.5 Hz, 3 H), 0.929 (d,J = 6.8 Hz. 3 H), 0.669 (q,J = 12.0 HZ, 
1 H, H-41); 13C NMR (CLXl,, 100.6 MHz, data for the tran- 
rotamer) S 215.3, 208.7, 191.7, 16Y.2, 166.Y, 156.8, 141.1, 
138.Y, 136.2, 135.i, 132.8, 12Y.9, 128.7, 126.Y, 126.5, IO’).‘). 
104.8, 98.2, 84.6, X4.3, 76.0, 73.8, 66.7; MS (ESI+/NH’OAc) 
m/= 967 (M+NH,+), Y32. Data for compound lob: ‘H 
NMK (CDCI,, 400 MHz, 3.5:l mixture of trtirzr:ci~ amide 
rotamers; data for the tru,ls-rotamer): 6 7.302 (d,_l = 1.8 Hz, 1 
H,Ar H-5’), 6.350 (dd,J = 14.6, 10.9 Hz, 1 H, H-4), 6.292 (dd, 
J= 3.0, 1.X Hz, 1 H,Ar H-4’),6.190 (dd,_l= 14.6, 10.4 Hz, 1 
H, H-3), h.(J34 (br d,] = 10.9 Hz, 1 H, H-5), 6.OlY (d,J = 
3.0 Hz, 1 H,Ar H-3’). 5.390 (d,] = 10.3 Hz, 1 H, H-26), 5.327 
(dd,J = 14.7,9.4 Hz, 1 H, H-l), 5.24-5.09 (III, 2 H, H-23 and 
H-Z)), 4.2Y4 (br s, H-28), 4.116 (d,J = 3.1 Hz, 1 H, H-29), 
3.805 (s, 1 H, OH-13), 3.78-3.72 (III, 1 H, H-Y), 3.524 (br d,J 
= 15.0 Hz, 1 H, H-16),3.469 (dd,J= 11.7,3.6 Hz, 1 H. H-7), 
3.3Yl (s, 3 H), 3.335 (s,3 H), 3.245 (dq,J = 10.3 (d), 6.6 Hz, 1 
H, H-25), 2.‘)4-2.89 (m, 1 H, H-42), 2.763 (dd,J = 17.7, 
2.8 Hz, 1 H, H-23), 2.360 (dd,_l = 17.7, 8.4 Hz. 1 H, H-23), 
1.825 (s, 3 H), 1.662 (s,3 H), 1.058 (d,J = 6.4 Hz. 3 H), 0.973 
(d.J = 6.5 Hz, 3 H), 0.924 (d,J = 6.4 Hz, 3 H), 0.888 (d.1 = 
6.4 Hz, 3 H), 0.883 (d,J = 6.5 Hz, 3 H), 0.633 (q,J = 11 .f, Hz, 
1 H, H-41); “C NMR (CDCl,, 100.6 MHz, data for the IYNMS- 
rotamer) 6 211.0, 207.2. 196.3, 16Y.6, 166.0, 155.4, 141.5. 
140.0, 137.8, 134.5, 131.2, 128.3. 123.6, 123.8, 110.1, 106.3, 
9X.5, 84.3, X3.7, 76.3, 73.9, 73.8, 68.3; MS (ESI+/NHJ1Ac) 
m/z 972 (M+Na+). 967 (M+NH,+). 
Preparation of compound 73 
To a solution of rapamycin (50 mg, 0.055 mmol) in CH,Cl, 
(1 ml) at 0 “C was added water (0.2 ml) followed by 2,3- 
dichloro-5,6-dicyano-1,4benzoquinone (DDQ) (25 mg, 
0.109 mmol). After 2 min the reaction is complete by thin- 
layer chromatography and the mixture was partitioned 
between EtOAc and saturated NaHCOj (0.5 ml). Puritication 
by silica gel chromatography afforded compound 13 (32 mg, 
65 (%I). ‘H NMR (CDCl,. 400 MHz, 3:1 mixture of tuans:cis 
amide rotamers; data for the tmtrs-rotamer): 6 7.146 (d,_l = 
10.X Hz, 1 H, H-5), 6.633 (dd,j = 13.‘). 10.6 Hz, 1 H, H-3), 
6.4’)s (dd,] = 14.Y, 10.8 Hz, 1 H. H-4), 6.224 (dd,] = 15.1, 
10.6 Hz, 1 H, H-2), .5.660 (dd,J = 15.1, 9.3 Hz, 1 H, H-l), 
5.413 (d,] = 9.0 Hz, 1 H. H-26), 5.25-5.20 (III, 1 H, H-X!), 
5.151 (d,J = 4.6 Hz, 1 H, H-20), 1.820 (s, OH-I.?), 4.53-4.47 
(III, 1 H, H-Y), 4.305 (br d,J = 4.7 Hz, 1 H. H-28). 3.090 (d.J 
= 4.7 Hz, 1 H, H-2’)), 3.387 (s, 3 H), 3.349 (s, 3 H), 3.223 (dd, 
1 = 15.4, 9.0 Hz, 1 H, H-S), 2.942.88 (m, 1 H. H-42), 2.362 
(ddJ = 15.4,3.7 Hz, 1 H, H-8), 1.862 (s,3 H), 1.804 (s. 3 H), 
1.080 (d,J = 6.5 Hz, 3 H), 1.027 (d.1 = 6.8 Hz, 3 H), O.Y80 (d, 
J = 6.6 Hz, 3 H), O.Y34 (d,_l = 6.7 Hz, 3 H), 0.847 (d.J = 
6.6 Hz, 3 H), 0.655 (q,J = 11.7 Hz, 1 H, H-41): “C NMR 
(CDCl,, 100.6 MHz, data for the fr[~tz~-rotamel-): 6 212.5, 
208.1, 199.5, 197.7, 169.2, 166.6, 143.6, 13Y.X. 130.1, 136.7. 
135.9, 130.5, 127.3, 125.8, 9Y.0, 85.2, X4.1, 83.3. 77.2, 76.4, 
74.7,73.9,6X. 1; MS (ESIf/NHJOAc) m/z 020 (M+Na+). 013 
(M+NH,+), 898, 880; UV (MeOH) hllldY 318 nm. 
FKBPl2 assays 
Apparent rotamase mhibition constants, K1 ~pp, were deter- 
mined using the chymotrypsin-coupled assay previously 
reported [18] and are used here as an approximate measure of 
ligand binding affinities. 
Splenocyte proliferation assays 
Spleen cells from BDFl female mice were established in 
RPM1 with IO ‘%, fetal calf serum at 5 x 10” mm’. One 
hundred I.LI aliquots of this suspension (5 x 10” cells) were dis- 
pensed into 96-well round-bottomed microtiter plates (Linbro, 
Flow Laboratories). Concanavalin A (5 p,g mm’) was added as 
the mitogenic stimulus and the final volume in the microtiter 
wells w~as adjusted to 200 ~1 with RPMI. Cell cultures were 
incubated for 72 11 at 37 C in a 5 ‘% CO, atmosphere and 
pulsed with 0.5 FCi -iH-thynlidine (specific activity 2.00 Ci 
mmol-‘) for- the last 18 h of the 72 h culture. The cells were 
harvested on an automated multiple sample harvester and cell- 
associated radioactivity counted in a Beckman liquid scintilla- 
tion counter. The results are expressed as the mean values 
derived from quadruplicate measurements. Cell viability was 
determined by trypan blue exclusion after 72 h of incubation. 
Compounds to be tested were added to the microtiter plates at 
the appropriate dilutions prior to the addition of cells. 
480 Chemistry & Biology 1995, Vol 2 No 7 
Yeast assays 
A standard agar diffusion assay was used to measure the yeast 
cytotosicity of the compounds. 2 x IO’ yeast cells were plated 
on 25 x 25 cm YEI’D plates and wells were made in the agar. 
One hundred ~1 of compound solutions of various concentra- 
tions (dissolved in 1 :l 11MSO:MeOH) were added to the 
wells. After 48 h of incubation at 30 ‘C the zones of inhibition 
of growth were measured. Linear regression analysis was 
apphed to plots of zone diameters versus the log ofconcentra- 
tion of compounds to obtain IC,? values. I<:,? is defined as the 
concentration of compounds in the well that would give a 
1~-m1~1 zone of inhibition. 
Crystallization and data collection 
Recombinant human FKBP12 purified from Ocllcricllin c-o/i 
was used at 10 rng I&’ in IO mM Tris-HCl, pH X.O.The four 
selected rapamycin analogs were dissolved in methanol and 
mixed with FKBPl2 at a 2: 1 molar ratio. The mixture was 
lightly vortexed. allowed to stand overnight to complete 
complex formation, and filtered. All crystallizations were 
done usmg the hanging drop method. Crystals of compounds 
4, 6a and 6b complexed with FKBP12 were obtained under 
slightly different conditions from those of the 
rFKBP12-rapamycin complex crystal (Table 3). Both micro- 
and macro-seeding techniques were used to improve the 
crystal size and quality. After 1 to 3 weeks, rectangular rod- 
like crystals with a maxinum Gze of 0.5 x 0.3 x 0.2 mm, 
lvhich were suitable for data collection, were obtained. 
Crystals of the FKBPl2-compound 9 complex were 
obtained under very different conditions (Table 3). Trigonal 
plate-shaped crystals with dimensions of 0.4 x 0.3 x 0.1 null 
were obtained in about 2 months. 
All four data sets were collected at room temperature on a 
San Diego multiwire area detector system mounted 011 a 
Rigaku RU-200 rotatmg anode X-ray source operating at 
50 kV x 130 mA. Crystals of the complexes with compounds 
4, 6a and 6b were isomorphous with FKB1’12-rapamycin, 
and formed in the orthorombic space group P2,2,2, with 
one molecule in the asymmetric unit. The FKBl’lZ- 
compound 9 complex crystallized in the monocl~nlc space 
group 1’2, with four molecules in the asymmetric unit. 
Structure determination and refinement 
The structure determination of the complexes with con- 
pounds 4, 6a and 6b was quite straightforward. Difference 
electron density maps were calculated using observed struc- 
ture factors, calculated structure factors of 
FKBPI 2-rapamycin and FKBPI 2%rapamycin phases. The dif- 
ference electron density maps were displayed with CHAIN 
[2-l]. The FO-Fc maps showed positive and negative peaks 
around the C-7 position that were consistent with the modi- 
fications expected. Based on these maps, nlodels were COII- 
ctructed and refined with the X-PLOR package [25]. 
Crystallographic parameters and refinement statistics are 
shown in Table 1. 
The structure of the FKBPl2-compound 9 complex was 
determined using molecular replacement. The complex con- 
tained four molecules in the asymmetric unit and a self rota- 
tion map showed that there are two non-crystallographic 
two-fold axes. The cross rotation search using the 
rapamycin~FKB1 1 ) 2 structure as a model revealed four clear 
peaks.T\vo peaks are related by a two-fold axis and the other 
tlvo peaks arc also related by a two-fold axis: these two pairs 
are I-elated by a 90’ rotation.The translation search \vas per- 
formed for each of the cross rotation solutions, and gave an 
unambigous solution for each solution. Rigid body refinement 
led to an R-factor of 0.345 (8-3 .&).The structure \v~as refined 
with X-PLOR using noncrystallograpliic symmetry restraints 
1251. Final refinement statistics are shomm in Table 4. 
Photoaffinity labeling 
Cell hues were obtained from the American Type Culture 
Collection. All cell lines Lvere cultured in suspension in RPM1 
1640 medium plus 10 o/;, fetal bovine serum and were regu- 
larly screened for mycoplasma contamination. Cells were 
incubated in 75 mM KCl, 10 mM HEPES pH 7.0, 0.2.5 M 
sucrose, 0.1 mM EL)TA, 0.1 mM EGTA, O..j rnM PMSF, 1 p.g 
mm’ pepstatin and leupeptin) for 15 min at 0 ‘C. NP40 was 
added to 0.1 ‘%I final concentration to lyse the plasma men- 
branes but not the nuclei. Extracts were centritilged at 200 x g 
for i nlin and at 130 000 x g for 30 min.The pellet from this 
step was resuspended in 0.15 M NaCl, 0.1 M NaH?PO,, 10 
mM Na,HPO, pH 7.4 (PBS) and incubated \vith 10 IIM 
radiophotoaftinity label, 17a, m the presence or absence of 10 
p,M recombinant FKBP12 and competitor compounds at 
room temperature for 30 min under subdued lighting. 
Samples were irradiated for 5 mm on ice under a 500W 
mercury vapor UV source. Bound label was separated iron1 
free by gel filtration chromatography on a Sephadex GO spin 
column presaturated with bovine serum albumin. Laenunli 
sample buffer \vas added to the protein fraction and run 
without boiling on 6-l 0 ‘%I polyacrylamide gels. Radioactive 
bands were visualized by autoradiography. 
Western blotting 
Cell extracts were run in parallel with recombinant FRAP on 
a 7 ‘% reducing SDS-polyacrylamide gel and proteins were 
transferred to nitrocellulote. Following a block with 5 ‘%, 
Carnation milk/PBS/O.5 ‘%I Txveen-20. the blot was probed for 
1 h with a 2 p,g ml- solution of affinity-purified (synthetic 
FRAP peptide) rabbit polyclonal antisera.The blot was washed 
with PBS/O.5 ‘%I Tween-30 and probed for 1 h with a 1:5000 
dilution of peroxidase-conjugated goat anti-rabbit antibody. 
Folloming a wash with f’BS/0.5 ‘%I Tiveen-20, the blot was 
developed with ECL reagent and exposed to fihn for 30 s.The 
same cell extract was photolabclcd and rm on a 7 ‘96 gel as 
Table 3. Crystallization conditions for selected FKBPl2 complexes. 
Rapamycin (1) Compound 4 Compound 6a Compound 6b Compound 9 
0.1 M phosphate 
(pH 6.0) 
0.4 M ammonium 
sulfate 
0.1 M phosphate 
(pH 5.9) 
2.5 M ammonium 
sulfate 
0.1 M phosphate 
cpH 5.9) 
0.3 M ammonium 
sulfate 
0.1 M Na acetate 
(pH 4.6) 
2.7 M ammonium 
sulfate 
2.0 M ammonium 
sulfate 
5 % isopropanol 
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Table 4. Crystallographic parameters and refinement statistics. 
Compound 4 Compound 6a Compound 6b Compound 9 
Space group 
Lattice parameters 
No. of complexes per 
asymmetric unit 
p*,2,*1 
a = 45.16 A 
b = 49.37 A 
c = 54.57 A 
1 
p*,2,21 
a = 45.45 /s 
b = 49.40 A 
c = 54.88 A 
1 
p2,*,21 
a = 45.28 A 
b = 49.22 8, 
c = 54.49 A 
1 
p*, 
a = 51.34 A 
b = 90.83 A 
c = 51.36 p\ 
b = 90.25 o 
4 
Refinement statistics 
R factor 0.183 0.180 0.174 0.183 
Rirer 0.206 0.204 0.188 0.216 
Resolution (A) 8.0-2.3 8.0-2.1 8.0-2.1 8.0-2.8 
RMS for bond distance (A) 0.007 0.007 0.007 0.009 
RMS for bond angle (“) 1.4 1.5 1.4 1.7 
RMS for improper torsion angle (“) 1.8 1.8 1.8 2.2 
No. of water molecules 70 61 73 - 
Average B-factor for main chain (A2) 19.4 19.8 15.5 7.52 
Average B-factor for all atoms (A2) 22.5 22.7 18.9 9.02 
above and exposed on a phosphorimaging screen to visualize 
radiolabeled proteins. 
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